Get started

Biotechnology

$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀 Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed. With more probabilities on our side, the likelihood of success is through the roof! 📈💥 Check it out, and let’s ride this wave together! 🌊 Stay tuned for more insights! 🔔 NFA #Trading #StockMarket #Biotech #Investing #HighFiveSetup
NASDAQ:VKTXLong
by RonnieV29
41
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by signalmastermind
MHUA Chinese Med Tech Penny StockMHUA is shown here on the daily chart. It is currently trading at about 90% off its high of the year. It is in the high volume area of the long term volume profile suggesting there is sufficent liquidity to support active trading. Recent volume spikes suggest buying volume increases with the spikes being about 10X relative volume. Price is over the POC line of the volume profile demonstrating that buying pressure exceeds selling pressure. Price is at or near to one standard deviation below the mean anchored VWAP and so in the undervalued area as confirmed by the RSI Stochastic < 20 %. Chart patterns include an engulfing " big ass " candle on 5/1 and a three-bar strike with another engulfing green candle on 5/12. Both of these could be considered long entry signals especially when supported by the price above the POC and the RSI. I will take a position risking 0.25% of the trading account to begin the trading week. I am targeting a gain of $15.00 per share being a 50% retracement back to the high YTD and a 300% return on investment. I will take a 100 share position and close 10 shares each time the price rises by $2.00. This will adequately mitigate the risk of a volatile penny stock while adequately rewarding the risk taken.
NASDAQ:MHUALong
by AwesomeAvani
ATAI Life Sciences | ATAI | Long at $1.30ATAI Life Sciences NASDAQ:ATAI , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is fast approaching my selected historical simple moving average (SMA). Often, but not always, the closer the price gets to this line, the higher chance there is for a fast upward move. In anticipation of this move, NASDAQ:ATAI is in a personal buy zone at $1.30. A word of caution: this is a pure technical analysis play and this company is not expected to be profitable for many, many years... Target #1 = $1.75 Target #2 = $2.50 Target #3 = $2.95
NASDAQ:ATAILong
by NicksAnalysis
KRRO a biotech company with earnings coming LONGKRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods . A recent analyst gave it an upside to 100 which is very favorable given its product line and track record with an all-time high of about $250 ( which is about 450% over current valuation) On the one-hour time frame, it has had a great week and is breaking out over its moving averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and $75.00 for most of the position in consideration of the analyst report.
NASDAQ:KRROLong
by AwesomeAvani
1
VTYX- a risky biotechnology penny stock LONGVTRX is on a 120 minute chart, currently trading at 90% off its ATH and 50% above its absolute long term support level. Price tried to cross above the long term mean VWAP 3 months ago but was rejected. I anticipate that in time it will try to so so again. From 3.3 to a target of 9 would be a move in the neighborhood of 300%. I will take a small position long trade here. This will be highly volatile. I will place a 25% stop loss to give VTRX room to roam for a couple of earnings periods. Once the price rises 25% I will convert to a trailing stop loss of 25% and make the then risk free trade low maintenance.
NASDAQ:VTYXLong
by AwesomeAvani
VOR - a b iotechnology penny stock LONGVOR is a on daily chart. It is a biotechnology startup which is burning cash. As a resut this is a speculative long trade for this company with products to treat leukemia ( blood cancer). Price has crossed over the POC line of the volume profile and also completed an anchored mean VWAP cross over. The Price Momentum Oscillator is reversing and buying volume has increased since the earnings report showed less of a loss than forecasted. I see 30% upside to the high pivot in mid-January. In conjunction with stop- loss set at the mean anchored VWAP this is a R to r of about 3.
NASDAQ:VOR
by AwesomeAvani
LCTX gets upgrade and is technically setup LONGLCTX on the weekly chart here has been falling since late 2021 and found support at the bottom of the high volume area of the volume profile and ranged between it and the POC line for the past 18 months. The is a high end clinically active biotechnology firm using stem cells to produce therapeutic cell lines . ( One experiment using the mammary glands of cows imbedded with cells that make insulin to make a weak milk solution containing insulin and then concentrate it for cheap insulin is quite remarkable- ) How about some special milk for to have with your sugar buzz) see more in the here link en.wikipedia.org Anyway, price rose into triple confluence- the anchored mean VWAP, the POC line, the upper boundary of the high volume area. A new analysis targets 7. Smart money is paying attention. My smart money is paying a lot of attention. I understand the science and the market that LCTX could reach in due time. I am not an insider but close. Enough said. My target is the tweezer tops of 2022 at 2.5 and so 65-70% upside in the near to intermediate term and after that maybe the analysis will revise the target up or down I am guessing the former.
AMEX:LCTXLong
by AwesomeAvani
VTYX- Buy the Pullback after a massive Bullish Surge LONGVTYX is an illustrative case in the trend is your friend. VTTX warmed up on Frbruary 20th and went parabolic on the next day and then faded while the moving averages and VWAP lines caught up. This is a buyable dip. It has now printed a couple of engulfing bullish candles. VTYX did less than a full 0.5 retracement as a sign of strength. I will take a long trade here targeting 16% upside to the top pivot of the recent price action. If the price can reach the target I will take half screening for higher-than-normal volatility. At present the volatility has mildly popped over the running mean telling me the continuation is on the ready. The plus here is earnings will report on March 24th so there is one month for traders to run the price up on this stock in that anticipation. Options are avaiable for call contracts expiring March 15th.
NASDAQ:VTYXLong
by AwesomeAvani
JAN on watch for bullish continuation LONGJAN had earnings but I cannot find the report. It is trading with heavy volume and it shows in the price action. Price has pulled back in the after-market in a standard Fibonacci retracement. A pullback is appropriate here as price has gained 250% in a month. I see the pullback as healthy and JAN is now well positioned for another bullish continuation. Volatility and volume supports the conclusion. I will set a stop loss at 10% and targets at 50%, 75% and 100% to take partial profits on an anticipated trend up. Alerts will be set onto a set of moving averages on the 30 minute time frame to detect death cross unders. Once profit is hits 10% I will change the stop loss to a trailing 10% stop loss and once above 75% make the trailing loss 5% and once over 100% change it to 3% so I can let the trade run itself from those orders.
JLong
by AwesomeAvani
2
LVTX a possible continuation medical technology penny stock LONGLVTX is a pharmaceutical company focused on biologicals for advanced prostate carcinoma. It recently secured a collaboration agreement with Merck to assist in the clinical trials and the financial burdens it imposes in a quid pro quo related to a share of product margins in the future. On the 15-minute chart, LVTX burst out of a long-standing consolidation cycle. The majority of shareholders per Yahoo Finance are insiders and institutions primarily hedge funds. These people are not clueless. This is a huge money inflow into the market cap. I intend to follow the money as I see that price has retraced to a good Fibonacci level and with the last candle may be on a reversal. I know that institutions tend to buy at the VWAP heavily and as price is below VWAP the impetus is to buy discounted from VWAP. I will follow the wisdom, experience and expertise of institutional traders. I will go long and assume the risk of more of a drop with an ATR stop loss. My goal in the trade is to get a 20% gain by the close on Monday. Getting into an insider trading move is tricky but it is interesting and can be profitable.
NASDAQ:LVTXLong
by AwesomeAvani
VERX ATH on Earnings LONGVERX on the 15 minute chart demonstrates printing a high tight bull flag pattern in its bullrun after the earnings report was a two line beat much like the one a quarter ago. VERX has impressed traders including this one who got in on the ride early. I will trade this like others recently with a similar pattern. I will hold during the consolidation and watch for a break above the flag regression channel. I will add upon the break and set a trailing stop loss of 5% upon a rise of another 5% keeping the profits safe while underway. See my ideas on SOUN DUOL, VTYX and a few others. Review the link to the pattern description here. See also my swing long trade ideas for this sector XBI and LABU.
NASDAQ:VERX
by AwesomeAvani
NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal timing? I will skip the conspiracy discussion. On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock that has been stuck in deeply undervalued territory for a significant time period is remarkable. I have bought far out of the money call options into 2025 and 2026 some only this past month. Those from this month are now up over 250% with 11 and 23 months to go to expiration. I see NVAX as a risky penny medical stock with a high reward potential relative to the risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out the competition when there is an opportunity and do not worry about the government crying monopoly when life-saving and life-extending medical products are involved. Time will tell. I expect insane profits.
NASDAQ:NVAX
by AwesomeAvani
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area of the volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing position here and again the next time I see a dip on the 15-30-minute chart. I look forward to take a piece out of the position after the next earnings report in about 75 days. I have an alert for relative volume when the running mean is exceeded on the 30 minute chart which notify me to take a look at the chart. This is illustrated on this longer time frame chart about the days around earnings but occurs from time to time from other events. As an aside, if NVAX gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be the leading candidate to do a takeover, friendly or otherwise.
NASDAQ:MRNALong
by AwesomeAvani
LABU a 3X leveraged ETF of biotechnology stocks LONGLABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged funds have time decay from the leveraging and management fees and are meant to be for short-term trading. Nonetheless, 100% in 3 months is an excellent return. I add to my position when I see a pullback on the 15-30 minute chart. If price rises more than 2% in a day I may take 1-2 shares off the position to realize some profit and recycle ( compound) into the next buy. According to those that follow sectors, LABU should outperform this year.
AMEX:LABULong
by AwesomeAvani
2
RZLT Biotechnology Penny Stock Reports in the next day LONGRZLT is a biotechnology company which has products in clinical development. Many are aware that means rigorous clinical trials before an FDA approval and a product line that generates earnings. Stock price is more about growth and potential more than anything else. That said the chart looks good and I sense there is momentum heading into earnings in the next day so this is a buy for me. I can see that price broke above a recent supply/resistance zone. This penny stock likely cannot be shorted so there is no selling pressure to be exerted until present longs have found their target. This can add to the momentum without the drag of that short selling. A penny here and a penny there it all adds up over time especially with compounding in active trading with penny stocks that have great range.
NASDAQ:RZLTLong
by AwesomeAvani
2
SRZN a Penny biotech LONGSRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been trending up for a week with a bit of a pause in the middle of it. It picked up 60% of its price while breaking out through the anchored VWAP lines and the volume profile. The far greater market is the former. It is priced at 90 or more off it's all-time high of about $160. IF it picks up hype from the last clinical trial getting a report and a calendared review by the, SRZN could reach for that all time high. This is speculative and risky as are most biotechnology penny stocks. They are trading news and potential not current net revenues. A small position with room in the stop loss for the average range and volatility is best. This is a typical high risk higher potential reward type of trade.
NASDAQ:SRZNLong
by AwesomeAvani
Pioneering Cancer Treatment with QINLOCK and VimseltinibIntroduction Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is at the forefront of developing innovative cancer treatments, with a keen focus on leveraging their proprietary switch-control kinase inhibitor platform. The company has made significant strides, particularly with its flagship product, QINLOCK, and the promising pipeline candidate vimseltinib, aiming for a transformative year in 2024. Revenue and Profit Forecasts Deciphera has projected an optimistic financial trajectory for 2023, with preliminary unaudited revenue for the fourth quarter estimated at approximately $47 million and full-year revenue expected to be around $162 million. This growth is largely attributed to the robust sales of QINLOCK, which alone contributed roughly $46 million in net product revenue in Q4 2023. The company's financial health is further underscored by its substantial cash reserves, amounting to approximately $352 million as of the end of 2023, ensuring operational and capital expenditure funding well into the second half of 2026​​​​. Growth Drivers The continued expansion and commercial success of QINLOCK in treating gastrointestinal stromal tumor (GIST) patients, along with the strategic rollout of vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT) and potential applications in chronic graft versus host disease (cGVHD), underscore Deciphera's growth trajectory. The company's strategic partnerships, such as the distribution agreement with GENESIS Pharma for QINLOCK in Central and Eastern Europe, are pivotal to its international market expansion​​​​. Recent Financial Performance Deciphera's earnings in Q4 2023 beat analyst expectations, reporting an EPS of -$0.54 against the anticipated -$0.58. This performance reflects a 32.9% increase in quarterly revenue year-over-year, indicating strong commercial execution and market acceptance of its products. Analysts remain optimistic about the company's future earnings, projecting gradual EPS improvement through 2025​​. Technical and Market Outlook Deciphera's technical indicators and market sentiment appear positive, buoyed by recent financial results and the potential for its pipeline candidates. The company's strategic focus on developing first-in-class and best-in-class treatments for cancer positions it well within the biopharmaceutical sector for sustained growth and innovation​​​​. Conclusion Deciphera Pharmaceuticals is poised for significant growth in 2024 and beyond, driven by its innovative product portfolio, strategic market expansions, and strong financial position. With QINLOCK's continued success and the anticipated commercial launch of vimseltinib, Deciphera is on the cusp of evolving into a self-sustaining, multi-product company. As it advances its mission to improve the lives of people with cancer, the biopharmaceutical firm remains a compelling entity within the oncology space, promising exciting developments for investors and patients alike. ---------------- NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
DLong
by olimchik
ROIV - BioTech reporting 2/13 as a LONG earnings tradeRoivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and volatility show both are heightened in the pre-earnings run- up. The last report in November was a double beat which is good prognosis for the one upcomings. This is a risky earnings play, ROIV does not yet make money. However, because it lost less than forecasted, buyer interest has increased. The call option for 2/16 for a strike of $12.50 is priced at $ 5.00 per contract. I suspect a long trade in shares may gain to $ 11.50 targeting the double top at the turn of the year for a projected gain upside of about 7% (with a stop loss of 2.5%). Considering that ROIV has gained 12% this past week, 7% in the next two days is about the same trend angle. As to the call contract, I have considered 100% return as my expections for the two days before the earnings. If earnings disappoint trader expectations and price fades I will sell to close the contract. If earnings is as expected, I will roll the contract forward into the March monthly and add a bit more capital into the trade.
NASDAQ:ROIVLong
by AwesomeAvani
1
INBS pumped on earnings crush= Watching for LONG maybeINBS crush earnings and went parabolic on an earnings beat. Basically, revenues fell but with belt-tightening and good CEO actions it bled less cash than expected. The tourniquet is working. The post-earnings pump was followed by a flush to the mid-Fib 0.5 support. Trader's got their reward and called it a weekend before lunch. The chop index fell into the consolidation zone and the MACD turned bearish. See the 5 minute chart image inserted to the left. The RSI lines are about 50 maybe with a crossdown impending. I have this on watch for a reversal up. Much will depend on general market strength on Monday. Biotechnology is projected as a hot sector now. This stock was among the hottest of the day. Hoping for a bullish continuation knowing that a trend down is likewise possible.
NASDAQ:INBS
by AwesomeAvani
2